Cellromax Science Cash Flow Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Net Income	2,966	3,817
Depreciation & Amortization	478.45	435.41
Loss (Gain) From Sale of Assets	-10.82	-11.85
Loss (Gain) From Sale of Investments	-127.93	-71.81
Stock-Based Compensation	336.48	-
Provision & Write-off of Bad Debts	-	8.37
Other Operating Activities	159.73	2,523
Change in Accounts Receivable	55.65	-26.06
Change in Inventory	-969.11	-589.25
Change in Accounts Payable	66.38	291.89
Change in Other Net Operating Assets	-1,170	-82.77
Operating Cash Flow	1,785	6,294
Operating Cash Flow Growth	-71.64%	-
Capital Expenditures	-78.64	-206.22
Sale of Property, Plant & Equipment	6.64	13.45
Sale (Purchase) of Intangibles	533.9	-2,547
Investment in Securities	1,437	-13,537
Other Investing Activities	2,122	-163.8
Investing Cash Flow	4,020	-16,441
Long-Term Debt Repaid	-265.24	-179.49
Net Debt Issued (Repaid)	-265.24	-179.49
Repurchase of Common Stock	-2,527	-17.27
Dividends Paid	-3,389	-
Other Financing Activities	-0	9,477
Financing Cash Flow	-6,181	9,280
Foreign Exchange Rate Adjustments	-0.41	0.55
Miscellaneous Cash Flow Adjustments	-	0
Net Cash Flow	-376.11	-865.86
Free Cash Flow	1,707	6,088
Free Cash Flow Growth	-71.97%	-
Free Cash Flow Margin	7.69%	28.15%
Free Cash Flow Per Share	150.16	585.32
Cash Interest Paid	28.49	30.35
Cash Income Tax Paid	1,131	918.62
Levered Free Cash Flow	1,702	-
Unlevered Free Cash Flow	1,733	-
Change in Working Capital	-2,017	-406.19

Source: S&P Global Market Intelligence. Standard template. Financial Sources.